T1	outcome 1400 1424	Grade 3 and 4 toxicities
T4	intervention 0 39	Gemcitabine, epirubicin, and paclitaxel
T5	control 47 93	fluorouracil, epirubicin, and cyclophosphamide
T6	age 626 640	18 to 75 years
T7	eligibility 641 673	with stage IV and measurable MBC
T9	total-participants 1051 1054	259
T10	intervention-participants 1074 1077	124
T11	control-participants 1088 1091	135
T12	outcome 1219 1230	median TtPD
T13	iv-cont-median 1235 1245	9.1 months
T14	cv-cont-median 1250 1260	9.0 months
T15	iv-bin-percent 1323 1328	62.3%
T16	intervention-participants 1349 1352	114
T17	cv-bin-percent 1358 1363	51.2%
T18	control-participants 1384 1387	129
T2	outcome 1436 1447	neutropenia
T3	outcome 1449 1465	thrombocytopenia
T8	outcome 1467 1473	anemia
T19	outcome 1475 1485	stomatitis
T20	outcome 1487 1508	neurosensory toxicity
T21	outcome 1514 1521	allergy
T22	outcome 1315 1318	ORR
T23	outcome 1612 1616	TtPD
T24	outcome 1621 1624	ORR
